Furthermore, evidence of the rivoceranib-induced increase in TUNEL-positive cells and fewer CD31-positive cells in treated tumour sections than in untreated tumour sections in both cell lines led us to hypothesise that rivoceranib reduced cell viability and tumour angiogenesis by inhibiting VEGF/VEGFR2 signalling. This evidence concerns the gene KDR and neoplasm.